Dr. David Jin M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE American: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters. Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, New York. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology. Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized by Leading Physicians of the World in 2015. Dr. Jin is qualified to serve as a director because of his role with us, and his extensive operational knowledge of, and executive level management experience in, the healthcare industry.
As the President, Chief Executive Officer y Director of Avalon GloboCare Corp, the total compensation of David Jin at Avalon GloboCare Corp is $934,722. There are 2 executives at Avalon GloboCare Corp getting paid more, with Lu Wenzhao having the highest compensation of $4,047,220.
David Jin is 52, he's been the President, Chief Executive Officer y Director of Avalon GloboCare Corp since 2016. There are 5 older and 4 younger executives at Avalon GloboCare Corp. The oldest executive at Avalon GloboCare Corp is Wilbert Tauzin, 76, who is the Director.
David's mailing address filed with the SEC is C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9, SUITE 3100, FREEHOLD,, NJ, 07728.
Over the last 8 years, insiders at Avalon GloboCare Corp have traded over $2,500,000 worth of Avalon GloboCare Corp stock and bought 898,876 units worth $1,418,962 . The most active insiders traders include Wenzhao Lu, Luisa Ingargiola y Steven Andrew Sanders. On average, Avalon GloboCare Corp executives and independent directors trade stock every 157 days with the average trade being worth of $446,629. The most recent stock trade was executed by Wenzhao Lu on 1 April 2020, trading 645,161 units of AVCO stock currently worth $1,000,000.
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Avalon GloboCare Corp executives and other stock owners filed with the SEC include: